Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Metman, L. V.
Right arrow Articles by Chase, T. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Metman, L. V.
Right arrow Articles by Chase, T. N.
NEUROLOGY 1997;49:711-713
© 1997 American Academy of Neurology

Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease

L. Verhagen Metman, MD, P. van den Munckhof, BS, A. A. G. Klaassen, BS, P. Blanchet, MD, PhD, M. M. Mouradian, MD and T. N. Chase, MD

From the Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.

Address correspondence and reprint requests to Dr. Thomas N. Chase, National Institutes of Health, Building 10, Room 5c103, 10 CENTER DR MSC 1406, Bethesda, MD 20892-1406.

The levodopa (LD) dose-antiparkinsonian response relationship becomes progressively steeper with advancing Parkinson's disease (PD). To establish the dose-response profile for the dyskinesiogenic effect of LD, we administered intravenous LD over a wide dose range to 25 patients with advanced PD. As expected in these patients with nonexistent therapeutic windows, the threshold doses (TD) for both motor effects were similar. Just around the TD, the relationship between LD dose and the magnitude of antiparkinsonian and dyskinesiogenic responses inclined steeply, reaching a plateau above 1.5 x TD. Response duration, however, continued to increase. The findings suggest that attempts to ameliorate dyskinesias in advanced PD patients by giving smaller, more frequent LD doses may be counter-productive due to shorter motor responses, more "off" time, and dose failures, while some may, in fact, benefit from higher LD doses to assure a full response and prolong its duration.

Received March 12, 1997. Accepted in final form April 10, 1997.




This article has been cited by other articles:


Home page
 Sci Transl MedHome page
B. Jarraya, S. Boulet, G. Scott Ralph, C. Jan, G. Bonvento, M. Azzouz, J. E. Miskin, M. Shin, T. Delzescaux, X. Drouot, et al.
Dopamine Gene Therapy for Parkinson's Disease in a Nonhuman Primate Without Associated Dyskinesia
Science Translational Medicine, October 14, 2009; 1(2): 2ra4 - 2ra4.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
J. Lee, W.-M. Zhu, D. Stanic, D. I. Finkelstein, M. H. Horne, J. Henderson, A. J. Lawrence, L. O'Connor, D. Tomas, J. Drago, et al.
Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia
Brain, June 1, 2008; 131(6): 1574 - 1587.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
R. de la Fuente-Fernandez, V. Sossi, Z. Huang, S. Furtado, J.-Q. Lu, D. B. Calne, T. J. Ruth, and A. J. Stoessl
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias
Brain, December 1, 2004; 127(12): 2747 - 2754.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Aubin, P. Barneoud, C. Carter, D. Caille, N. Sontag, C. Marc, J. Lolivier, A. Gardes, C. Perron, A. Le Kim, et al.
SL25.1131 [3(S),3a(S)-3-Methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a New, Reversible, and Mixed Inhibitor of Monoamine Oxidase-A and Monoamine Oxidase-B: Biochemical and Behavioral Profile
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 1171 - 1182.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. Jankovic
Levodopa strengths and weaknesses
Neurology, February 1, 2002; 58(90001): S19 - 32.
[Abstract] [Full Text]

Home page
 NeurologyHome page
M. Zappia, D. Bosco, M. Plastino, G. Nicoletti, D. Branca, R. L. Oliveri, U. Aguglia, A. Gambardella, and A. Quattrone
Pharmacodynamics of the long-duration response to levodopa in PD
Neurology, August 1, 1999; 53(3): 557 - 557.
[Abstract] [Full Text]

Home page
 NEJMHome page
A. E. Lang and A. M. Lozano
Parkinson's Disease- Second of Two Parts
N. Engl. J. Med., October 15, 1998; 339(16): 1130 - 1143.
[Full Text] [PDF]

Home page
 NeurologyHome page
V. L. Metman, D. P. Dotto, R. Natte, P. van den Munckhof, and T. N. Chase
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease
Neurology, July 1, 1998; 51(1): 203 - 206.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. J. Blanchet, S. Konitsiotis, and T. N. Chase
Motor Response to a Dopamine D3 Receptor Preferring Agonist Compared to Apomorphine in Levodopa-Primed 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Monkeys
J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 794 - 794.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by AAN Enterprises, Inc.